Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PD-1/L1
Pharma
AACR: Detailed data spark hope for Merck combo in NSCLC
Researchers plan to run biomarker analyses of patients in the KEYLYNK-008 trial to see whether any subsets may benefit from the addition of Lynparza.
Angus Liu
Apr 9, 2024 1:16pm
AstraZeneca’s Imfinzi tackles another type of lung cancer
Apr 5, 2024 10:22am
Novo, Novartis, Merck KGaA, Kyowa Kirin—Fierce Pharma Asia
Mar 22, 2024 8:45am
Merck’s Lynparza-Keytruda plan sputters in 2nd lung cancer trial
Mar 21, 2024 10:28am
BMS shoots for 1L liver cancer again with Opdivo, Yervoy combo
Mar 20, 2024 10:18am
AZ, GSK make case for broad I-O uses in endometrial cancer
Mar 18, 2024 11:05am